Keyword: Johnson & Johnson

Aro Biotherapeutics raised $13 million to build its team and advance its centyrin pipeline, which includes a candidate for non-small cell lung cancer.

In the 57 patients who received the treatment, the overall response rate was 88%, with 74% having a complete response.

Vedanta’s pact with J&J on microbiome therapies has moved to the clinical stage, triggering a $12 million milestone payment.

Johnson & Johnson Vision inked a $26.35 million collaboration with the Singapore Eye Research institute focused on treating nearsightedness.

J&J picked up the rights to the CD28 antagonist for €10 million upfront in 2016, but clinical progress stalled following the deal. 

Roche is licensing Halozyme's Enhanze drug delivery platform for three new targets. Halozyme could receive up to $165 million in milestones per target.

Johnson & Johnson is broadening access to its startup incubator with a new remote networking hub hosted by the University of Pennsylvania.

The data could tee Bayer up to compete with Johnson & Johnson and Pfizer for a previously underserved population of prostate cancer patients.